Browse ATS 2021 Abstracts

HomeProgram ▶ Browse ATS 2021 Abstracts

ATS 2021 will feature presentations of original research from accepted abstracts. Mini Symposia and Thematic Poster Sessions are abstract based sessions.

Please use the form below to browse scientific abstracts and case reports accepted for ATS 2021. Abstracts presented at the ATS 2021 will be published in the Online Abstract Issue of the American Journal of Respiratory and Critical Care Medicine, Volume 203, May 3, 2021.

Search Tips:

  • Use the keyword search to search by keyword or author's name.
  • Filter your search results by selecting the checkboxes that apply.
  • Click on "Clear" to clear the form and start a new search. .

Search results will display below the form.

Post-Hospitalization Mortality in Patients with Idiopathic Pulmonary Fibrosis: Data from the IPF-PRO Registry

Session Title
A1864 - Post-Hospitalization Mortality in Patients with Idiopathic Pulmonary Fibrosis: Data from the IPF-PRO Registry
Author Block: H. Kim1, L. D. Snyder2, A. Adegunsoye3, M. L. Neely2, S. Bender4, E. S. White4, C. S. Conoscenti4, M. E. Strek3, on behalf of the IPF-PRO Registry investigators; 1University of Minnesota, Minneapolis, MN, United States, 2Duke Clinical Research Institute, Durham, NC, United States, Duke University Medical Center, Durham, NC, United States, 3Section of Pulmonary, Critical Care Medicine, University of Chicago, Chicago, IL, United States, 4Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States.
Rationale: Idiopathic pulmonary fibrosis (IPF) is associated with a high risk of hospitalization and a poor prognosis. The IPF-PRO Registry is a multicenter, observational registry of patients with IPF in the US. We used data from this registry to evaluate the risk of mortality after hospitalization in patients with IPF. Methods: Patients with IPF that was diagnosed or confirmed at the enrolling center in the previous 6 months were enrolled into the IPF-PRO Registry between June 2014 and October 2018. Patients are followed prospectively, with follow-up data collected approximately every 6 months. Data for this analysis were extracted from the database in June 2020. We examined the association between hospitalization (all-cause and respiratory-related, in the opinion of the investigator) and mortality during the hospitalization or within 90, 180 and 360 days of discharge using univariable and multivariable Cox regression models. The multivariable models included hospitalization as a time-dependent covariate, age, body mass index (BMI), FVC % predicted, DLCO % predicted, oxygen use at rest and history of coronary artery disease or heart failure at enrollment. Results: A total of 1002 patients were enrolled at 46 sites. One hospitalized patient was excluded due to incomplete data. Over a maximum follow-up of 67.0 months (median: 23.7 months), 550 patients (54.9%) were hospitalized. Of the hospitalized patients, the first hospitalization was respiratory-related in 45.5% of cases. Over the follow-up period, 28.5% of patients with ≥1 hospitalization and 38.2% of patients with ≥1 respiratory-related hospitalization died. There were significant associations between both all-cause hospitalization and respiratory-related hospitalization and risk of mortality within 90, 180 and 360 days of discharge in both univariable and multivariable models (Figure). The risk of mortality was greater following respiratory-related hospitalization than non-respiratory hospitalization. Conclusions: Hospitalizations are common among patients with IPF and are associated with a high risk of mortality in the year following discharge, particularly among patients hospitalized for a respiratory-related cause.